Cytosorbents Corp (CTSO) FinancialsCTSOCytosorbents Corp

Cytosorbents Corp (CTSO) generates its revenue primarily from CytoSorb and other sales, which accounts for 100.0% of total sales, equivalent to $9.48M. Understanding this concentration is critical for investors evaluating how CTSO navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Cytosorbents Corp maintains a gross margin of 73.18%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -24.58%, while the net margin is -45.85%. These profitability ratios, combined with a Return on Equity (ROE) of -336.21%, provide a clear picture of how effectively CTSO converts its operational activities into shareholder value.

In the context of the broader market, CTSO competes directly with industry leaders such as LFWD and PMI. With a market capitalization of $21.09M, it holds a significant position in the sector. When comparing efficiency, CTSO's gross margin of 73.18% stands against LFWD's 40.90% and PMI's 79.08%. Such benchmarking helps identify whether Cytosorbents Corp is trading at a premium or discount relative to its financial performance.

Cytosorbents has shown fluctuating revenue with $9.6 million in Q2 2026, but continues to report net income losses, including a $4.4 million loss in the same quarter. The gross margin remains relatively strong at 73.18%, but the overall financial health is concerning due to high debt levels and negative earnings.